Loading...
Loading...
KZR| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.2M |
| Gross Profit | -0.2M |
| Operating Expense | 26.8M |
| Operating I/L | -26.8M |
| Other Income/Expense | 2.5M |
| Interest Income | 2.9M |
| Pretax | -24.3M |
| Income Tax Expense | 2.9M |
| Net Income/Loss | -24.3M |
Kezar Life Sciences, Inc. is a clinical-stage biotechnology company focused on developing small molecule therapeutics for immune-mediated diseases and cancer. Its lead product candidate, KZR-616, is a selective immunoproteasome inhibitor undergoing Phase 2 clinical trials for lupus nephritis, dermatomyositis, and polymyositis, as well as Phase 1b trials for systemic lupus erythematosus and lupus nephritis. The company also has preclinical products, including KZR-261, a protein secretion inhibitor, and KZR-TBD for oncology and immunology treatments.
